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Abstract: Despite the continuous advancement in neurosciences as well as in the knowledge of
human behaviors pathophysiology, currently suicide represents a puzzling challenge. The World
Health Organization (WHO) has established that one million people die by suicide every year, with
the impressive daily rate of a suicide every 40 s. The weightiest concern about suicidal behavior
is how difficult it is for healthcare professionals to predict. However, recent evidence in genomic
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studies has pointed out the essential role that genetics could play in influencing person’s suicide
risk. Combining genomic and clinical risk assessment approaches, some studies have identified
a number of biomarkers for suicidal ideation, which are involved in neural connectivity, neural
activity, mood, as well as in immune and inflammatory response, such as the mammalian target of
rapamycin (mTOR) signaling. This interesting discovery provides the neurobiological bases for the
use of drugs that impact these specific signaling pathways in the treatment of suicidality, such as
ketamine. Ketamine, an N-methyl-d-aspartate glutamate (NMDA) antagonist agent, has recently
hit the headlines because of its rapid antidepressant and concurrent anti-suicidal action. Here we
review the preclinical and clinical evidence that lay the foundations of the efficacy of ketamine in the
treatment of suicidal ideation in mood disorders, thereby also approaching the essential question of
the understanding of neurobiological processes of suicide and the potential therapeutics.
Keywords: mood disorders; dopamine; serotonin; glutamate; postsynaptic density; antipsychotics;
antidepressants; NMDA; suicide; ketamine; esketamine
1. The Roots of Suicide: Current Advances in Neurobiology of Depression and
Suicidal Behaviors
1.1. A Global Phenomenon
Among 800,000 people commit suicide every year, and even many more people attempt suicide [1].
The World Health Organization has estimated that 78% of suicide attempts occur in low- and
middle-income countries, and that in 2015 suicide was the second leading cause of death amongst
15–29-year-old young adults globally [2].
A large body of evidence reports that 90% of suicide victims suffer, or have suffered, from
psychiatric disorders [3,4], as well as 50% of people committing suicide has been affected by major
affective disorders (e.g., major depressive disorder, bipolar disorder) [5,6]. However, alcohol and drug
abuse, schizophrenia, and personality disorders have been often associated to suicide, together with
affective disorders [7].
As mentioned, the vast majority of people attempting to their own lives belong to
low/middle-income social classes, therefore there is a large amount of data claiming that the ten-year
economic crisis would have influenced suicide rates, probably by reducing and impairing cares for
mental health patients [8].
1.2. The Process of Suicidal Behavior
From an ethological and psychobiological point of view, suicidal behavior can be seen as a
complicated process in which genetic, neurobiological, environmental and psychological factors
imbricate in order to develop the final outcome [9,10]. However, how these factors interact with each
other represents an issue so entangled that it is actually extremely difficult to predict who would
commit a complete suicide and when [11–13]. Indeed, A recent meta-analysis on suicide risk reported
that 95% of high-risk patients (i.e., displaying multiple suicide-related characteristics defining a high
propensity to suicidal mortality) usually do not attempt suicide, whereas 50% of low-risk patients do,
thus confirming the complexity of suicidal behavior processes [14].
Recent research breaks down suicidal behavior into its chronological parts: the ideation, the
planning, the attempt/attempts, and the complete suicide [15]. Each phase may have a different
duration and intensity, and, although suicidal attempts cannot chronologically precede ideation, they
do not always follow it as expected, since suicidal ideas are not always followed by suicidal attempts.
However, even if suicidal ideation should be manifest, it has been demonstrated in several studies
that clinical interventions may not be efficacious [16]. A lot of studies have reported high rates of
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persistence of suicidal ideation in people diagnosed with psychiatric disorders, despite adequate
treatments. For example: in first-episode psychosis patients, 33% report moderately stable and 7%
moderately increasing persistent suicidal ideation over two years [17]; 6.3% of patients with diagnosed
depression may experience high suicidal ideation despite 4 months of treatment [18]; 14% of bipolar
disorder patients endure suicidal ideation over 6 months of treatment [19]; and lastly, even after
hospitalization due to acute attempts or acute ideation, suicidal thoughts have been demonstrated to
persist in adolescent patients even after 12 months following discharge from treatment [20]. Anyway,
some studies suggest there are possible predictors of suicide, even if ideation is not completely
expressed. For instance, Köhler-Forsberg and colleagues have reported that suicide may be predicted
by higher baseline depression scores in bipolar patients with persistent ideation [19]. Furthermore,
suicide attempts may be considered a significant risk factor for possible completed suicide [21].
1.3. Integrated Theories of Suicide
Modern theories try to converge multiple levels of analysis, such as neurobiological (i.e.,
dysfunctions in the hypothalamic-pituitary axis, abnormal noradrenergic/serotonergic/dopaminergic/
glutamatergic neurotransmissions, neuroinflammatory dysregulation) and sociological hypotheses
(i.e., the relationship between the individual personality and social/environmental stressful factors),
in order to develop and integrated model aiming at finding a “biosignature” of suicide [22–24].
For example, a recent study—based on preclinical evidence of the association between the short allele
of the 5-HTT (serotonin transporter) gene-linked polymorphic region and greater susceptibility to stress
events [25–27]—tested the hypothesis that variants in the 5-HTT gene might influence dysfunctional
adaptation to stressful events (gene-by-environment hypothesis) by analyzing the birth cohort study
of 1037 people in the Dunedin Multidisciplinary Health and Development Study, thus finding that
individuals yielding the short allele of the 5-HTT promoter polymorphism exhibited more depressive
symptoms, and more propensity to suicidal behaviors in relation to stressful life events than individuals
homozygous for the long allele [28].
Moreover, an extensive family-based genetic study analyzing suicide attempters switched the
attention from “classical” serotonergic-related pathways to the involvement of GABA and glutamate
neurotransmission in suicidal behaviors. Indeed, Sokolowski et al. found that GRIN2B (a glutamate
NMDA receptor subunit gene) and ODC1 (a gene coding for ornithine decarboxylase, a rate-limiting
enzyme on the polyamine synthesis pathway) seem to be associated with severe suicide attempts, as
well as with serious physical assault in childhood and adolescence, which in turn increase the risk of
suicide attempts, thereby configuring a gene-by-environment interaction [29].
Finally, according to a diathesis-stress model, recent evidence points out that early stressful life
events may increase the diathesis for suicidal behaviors both by provoking epigenetic and neurological
changes (e.g., on serotonin neurotransmission, opioids, oxytocin, and HPA axis) and impacting on
neurobiological correlates underlying character traits that have been associated with susceptibility
to suicide risk (such as impulsivity, emotional dysregulation, poor attachment, chronic pessimism,
impaired cognition) (see [30] for an exhaustive review).
2. Cognitive Bases of Suicidal Behaviors: The Role of Glutamate Neurotransmission
2.1. Cognitive Dysfunctions in Suicide Attempters
As mentioned above, suicide may be envisioned as a complex process involving multiple
interactions amongst biological, psychological, and environmental factors. Recent researchers have
begun to place suicidal progression within a framework of cognitive schemas involving basic cognition
and individual reality interpretation (i.e., perceived burdensomeness, thwarted belongingness) [30].
Basic cognitive alterations have been studied from a neuropsychological point of view and found
to be related to abnormal neurocircuitry connections, especially in prefrontal-striatal brain circuits
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(ventrolateral orbital cortex, dorsolateral/dorsomedial prefrontal cortex, anterior cingulate gyrus) [31],
and probably to involve glutamatergic neurotransmission dysregulation in these areas [32].
Cognitive hypotheses of suicidal behaviors are based on the well-validated theories about acquired
capability for suicide. The interpersonal-psychological theory of suicidal behavior, elaborated by
Thomas Joiner in 2005 [33], suggests that completed suicides require three specific characteristics: a
sense of thwarted belongingness, a sense of burdensomeness, and an acquired capability for suicide,
which is characterized as the habituation to fear, pain, and death by means of continued and progressive
exposure to painful and provocative events, thereby causing a sort of desensitization. Moreover, the
acquired capability for suicide must necessary entangle with reasons to attempt suicide, in order to
finalize the progress to completed suicide. Different studies have reported that feelings of loneliness or
being unwanted, together with the will for auto-punishment, as well as the necessity of get relief from
a terribly distressing state of mind, may represent the more prominent reasons to commit suicide [34].
These theories may be re-examined from a “cognitive” point of view in order to identify the
putative cognitive mechanisms at the basis of suicidal behavior, such as the effects of the negative
thoughts and overwhelming emotions of affective patients on their perception of environmental
stimuli, which could be defined as attentional bias. Indeed, different studies have reported that often
psychiatric patients pay much attention to environmental cues that are specifically related to their
suffering, and in particular the sense of hopelessness, burdensomeness, and loneliness may cause
extreme difficulties in patients to find solutions to their problems other than suicide [35]. Attentional
bias may be measured by specific neuropsychological tests exploring executive functions, such as
the Stroop paradigm, which requests that patients name the color in which some words are written.
A recent study reported that depressed patients may perform defectively on the Stroop test, when
asked to name colors of suicide-related words [36]. These results confirm previous findings of worse
performances in memory, attention and working-memory tasks by non-violent, depressed patients
who have attempted suicide in the past, as compared to depressed non-attempters, and suggest that
executive dysfunctions in people who have attempted suicide may be related to specific forms of
suicidal behavior [37].
A particular mention should be made of the relationship between suicide and impulsivity, which
has been widely investigated. Impulsivity has been associated with suicidal behavior in a large
amount of studies [38] and it has been regarded as a heritable trait [39]. Impulsive decision-making
has been related to suicide attempts in bipolar patients [40], and depressed patients with higher
impulsivity have been reported to show higher rates of suicide attempts regardless of the severity
of their depressive symptoms [41]. Moreover, impulsivity and aggression have been both correlated
with high-lethality suicide attempts in borderline personality disorder patients, and associated with
abnormal volumes across multiple fronto-temporal-limbic regions deputed to cognitive control of
emotions and behavioral planning [42].
2.2. Glutamate Neurotransmission Dysregulation as the Foundation of Suicidal Cognitive Biases
Cognitive flexibility is a critical executive function that represents the ability to adapt behavior
in response to environmental changes. Its dysfunctions have been largely regarded as contributing
to the onset of several psychiatric diseases, such as depressive, bipolar, and anxiety disorders [43].
Functional studies have associated the deficits in cognitive flexibility showed by depressed patients to
specific alterations in the structure and connection of the prefrontal cortex (PFC) [44,45].
Glutamate neurotransmission dysregulation seems to represent the core neurobiological
foundations the abovementioned functional alterations. Indeed, reduced glutamate/glutamine and
GABA levels (positively correlated with each other) have been demonstrated in the prefrontal cortex
of unmedicated depressed patients using proton magnetic resonance spectroscopy [46]. In order to
corroborate these findings, reduced levels of NR2A and NR2B subunits of the N-methyl-D-aspartate
(NMDA) ionotropic glutamate receptors have also been found in postmortem PFCs of major depression
patients, together with a concurrent reduction in PSD-95, a scaffold postsynaptic protein that is
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essential in NMDA trafficking and transductional pathways, thus suggesting abnormalities in the
whole glutamate signaling in brain areas deputed to cognitive tasks [47]. In animal models, acute
stress may enhance glutamate neurotransmission in PFC [48], and the increase in glutamate-mediated
activation may potentiate working memory performances [49], whereas NMDA blocking impairs
cognitive flexibility [50].
Chronic stress, instead, may cause a sustained impairment by means of the suppression of
glutamate receptors in PFC, and may consequently provoke its dysfunctionality [51]. A recent
preclinical work has demonstrated that chronic stress may resemble the PFC-dependent attention
set-shifting deficits induced by NMDA blockade, and that these deficits are associated with an
attenuated afferent activation of the PFC as well as a reduced acute stress-induced glutamate efflux in
PFC, thus configuring impaired cognitive flexibility responses [52].
Several studies have confirmed the crucial role in suicidal behavior of glutamate
neurotransmission dysregulation in cognition-associated brain areas. Indeed, glutamine synthetase-
expressing glial cells have been found significantly elevated in the dorsolateral PFC and in orbitofrontal
cortex of schizophrenia patients who completed suicide, as compared with controls and non-suicidal
patients, thereby suggesting that a disruption in glutamate-glutamine-GABA cycle in these brain areas
may have a significant impact on suicidal behavior [53]. In suicidal patients a significant increase in
glutamic acid decarboxylase (GAD, the enzyme deputed to GABA synthesis starting from glutamate)
neuropil has been reported in the hippocampus [54]. Finally, a selective PFC up-regulation of an
alternative full-length transcript of GAD has been recently observed in suicide-completer schizophrenia
patients [32].
As mentioned above, an extensive family-based genomic study reported a significant association
of GRIN2B (coding for a glutamate NMDA subunit) with severe suicide attempts, as well as a significant
gene-by-environment relation with a history of physical assault in childhood and adolescence,
increasing suicide risk [29].
Impaired glutamate neurotransmission in the cingulate cortex has been also directly correlated
with impulsivity and cognitive dysregulation [55]. A recent study demonstrated that glutamate levels
measured in cerebro-spinal fluid may be directly correlated with impulsive aggression in both subjects
diagnosed with personality disorders and healthy volunteers, independently from their pathology [48].
Moreover, given that clozapine has been universally recognized as a superior treatment for both
suicidality and aggression/impulsivity [56–58], the finding that this antipsychotic may potentiate
NMDA receptor function by inhibiting Sistem A-mediated glycine transport could account for its
differential therapeutic properties as compared to other antipsychotics for suicidal behavior [59].
3. Eradicating the Roots of Suicide: Neurobiological Bases of Anti-Suicidal Effects of Ketamine
3.1. Preclinical Evidence of Ketamine Antidepressant Effects
Modeling suicidal behaviors in animals represents a complex challenge, since suicide has not been
identified in any animal species despite the thousands of studies performed. In particular, the challenge
with animals is trying to model the process of ideation, will, and intention to suicide, which seem to
be characteristics peculiar to humans [60]. However, the most recent preclinical approaches aim at
modeling specific human endophenotypes that have been associated with the suicidal process. Some
pathways associated to suicidal behaviors, such as hypothalamic-pituitary-adrenal axis dysfunction
and stress, neurotransmission anomalies, neuroinflammatory and neuroendocrine changes, aggression,
impulsivity, and cognitive biases may be well modeled in animals, thereby permitting testing of the
efficacy of renowned (clozapine, lithium) and newly-discovered potential anti-suicidal treatments,
such as ketamine, in eventually preventing suicide [61]. Here we describe the preclinical effects of
ketamine on neurobiological pathways associated with depressive behaviors in animal models and
potentially involved in human suicidal processes.
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Ketamine is a NMDA receptor antagonist that was approved in 1970 to be used as an anesthetic
drug. It has a 2.5 h blood half-life and is metabolized to norketamine and dehydronorketamine via
cytochrome P450 system.
Ketamine yields peculiar pharmacodynamic properties. It is a non-selective NMDA receptor
antagonist acting at opened channels, but several studies have identified multiple receptors interactions
of ketamine, such as with opioid sigma and mu receptors, serotonin 5HT3 receptors, muscarinic
receptors, α7 nicotinic acetylcholine receptors, and cathecolamines transporters [62,63].
Usually, ketamine is administered as a 1:1 racemic (S,R) mixture, and (S)-ketamine (esketamine)
has been demonstrated to display a higher affinity for phencyclidine NMDA binding sites as compared
to the (R) isomer [64].
Based on the early evidence that the NMDA non-competitive antagonist MK-801 might display
antidepressant properties by counteracting the stress-induced impairment in long-term potentiation
(LTP) in the hippocampus [65], a huge amount of studies have been performed demonstrating the
rapid antidepressant effects of ketamine in animal models. First studies reported that animals injected
with ketamine showed lesser despair behaviors during a forced swing test (FST) as compared to
controls [66]. Moreover, a direct correlation between reduction in immobility at the FST and increase in
hippocampal brain-derived neurotrophic factor (BDNF) was noted in successive studies, thus posing
the basis for the acknowledgement of the involvement of the tropomyosin receptor kinase B (TrkB)
signaling pathway in the antidepressant mechanisms of action of ketamine [67].
Finally, the fact that a pretreatment with NBQX, anα-amino-3-hydroxy-5-methylisoxazole-4-propionic
acid (AMPA) receptors inhibitor, might reduce the antidepressant effects exerted by ketamine during
the FST pointed out the essential role of postsynaptic AMPA receptors activation besides presynaptic
NMDA blockade in the molecular mechanisms underlying these actions [68]. Over the years, several
studies have corroborated the abovementioned results, refining and perfecting our knowledge on
the intra-neural underpinnings of ketamine antidepressant action. For example, in animal models
of chronic unpredictable stress there is evidence that depression-like behaviors are accompanied by
the hippocampal upregulation of inflammatory markers, such as of interleukin (IL)-1β, IL-6, tumor
necrosis factor-α (TNF-α), indoleamine 2,3-dioxygenase (IDO), and kynurenine (KYN)/tryptophan
(TRP) ratio, which can be attenuated by the administration of sub-anesthetic doses of ketamine [69].
Moreover, in animal models of maternal deprivation, ketamine has been demonstrated to reverse
depressive-like behaviors after a single dose with sustained antidepressant effects, as well as to protect
from oxidative stress-induced brain damage by increasing the activities of superoxide dismutase
and catalase that were reduced in deprived animals [70]. Also, the same authors reported that
the administration of ketamine to maternal-deprived rats may attenuate the induced increase in
inflammatory cytokines (TNF-α and IL-1 in serum, and in IL-6 in serum and cerebrospinal fluid) [71].
In order to confirm the great potential of ketamine in the therapeutic approach to treatment-resistant
depression (TRD), some studies have demonstrated that this compound may induce significant
reduction in despair behaviors during FST also in repeated corticosterone-treated animals (which is a
model of TRD) [72].
The vast majority of studies concerning antidepressant effects of ketamine have localized the
principal sites of action of this compound in PFC and hippocampal brain areas. Indeed, ketamine
microinfusion in infralimbic PFC has been demonstrated to be able to mimic the antidepressant effects
of systemic ketamine infusion, and these effects may be also mimicked by optogenetic stimulation of
the same brain area, being related to the increase in number and function of spine synapses of layer V
pyramidal neurons [73]. Ketamine has also been reported to increase hippocampal-PFC connectivity
(which has been demonstrated to be impaired in depression) in both humans and animals by inducing
an hyperglutamatergic state measurable by means of an electroencephalographic gamma band power
enhancement [74,75].
However, besides the peculiar modulation of oxidative stress enzymes and inflammatory markers,
as well as the impact on multiple neurotransmissions, all the scientific literature on ketamine converges
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on the evidence that the antidepressant effects of this compound are essentially mediated by the
AMPA-dependent activation in PFC and hippocampus of two crucial transduction pathways: the
mammalian target of rapamycin (mTOR) and brain-derived neurotrophic factor (BDNF) signaling.
3.2. mTOR and BDNF: The Molecular Cores of Ketamine Antidepressant and Anti-Suicidal Action
mTOR is a highly conserved serine/threonine protein kinase, which has been described to
modulate several important cell functions, such as metabolism, proliferation, death, and protein
synthesis [76]. mTOR exerts its regulatory action on protein synthesis through the inhibitory
phosphorylation of the repressor of mRNA translation, eukaryotic initiation factor 4E-binding protein
(4E-BP1), as well as the activating phosphorylation of S6 kinase (S6K1) [76]. Rapamycin may
inhibit mTOR functions by modulating its upstream regulators, the protein kinase B (PKB/Akt) and
extracellular signal-related kinase (ERK), which in turn may modulate the tuberous sclerosis complexes
(TSC1, TSC2), which are mTOR inhibitors [77]. The glucose synthase kinase-3 (GSK3) may inhibit mTOR
functions through the activation of TSC1 and TSC2 [78]. The final regulation of protein translation by
mTOR is exerted via the eukaryotic elongation factor 2 (eEF2), which may be inhibited by S6K1 [76].
mTOR may associate in two different complexes: mTOR complex 1 (mTORC1), which requires the
regulatory-associated protein of mTOR (Raptor) and is modulated by rapamycin [79], and mTOR
complex 2 (mTORC2), which is rapamycin-independent [80].
A lot of brain physiological processes have been described to be underlain by mTOR, such as
neuronal excitability and survival, synaptic potentiation/depression, dendritic spine activity-induced
maturation, and memory formation (see [80] for review). Therefore, it is not surprising that mTOR
has been regarded as involved in multiple neuropsychiatric disorders, and particularly in depressive
disorders, both in humans and in animal models [81,82].
Recent genomic studies have identified molecules belonging to mTOR signaling as valuable
biomarkers for suicidal behaviors [83]. Moreover, mTOR has been specifically associated to suicide
attempts in US veterans [84].
A pivotal study by Li et al. has demonstrated that the modulation of mTOR-dependent pathways
is crucial for ketamine-induced antidepressant effects [85]. mTOR, indeed, represents an essential
target of ketamine in the prefrontal cortex of animal models of depressive states, and the activation
of mTOR by ketamine also provokes the increase in mRNA and protein levels of activity-regulated
cytoskeletal-associated protein Arc, synapsin I, postsynaptic density protein 95 (PSD95), and GluR1
(an AMPA receptor subunit), all of which have been demonstrated to play core roles in synaptic
plasticity [85], as shown in Figure 1. Moreover, a successive study by the same group reported
that ketamine may not only attenuate anhedonic and anxiogenic behaviors induced by chronic
unpredictable stress in animal models, but also revert the stress-induced decrease in expression
levels of synaptic proteins (PSD95, synapsin I, GluR1), spine number, and frequency of excitatory
postsynaptic currents [86].
The antidepressant effects of ketamine via mTOR activation have been demonstrated to require
GluN2B-containing NMDA receptors in PFC, whose deletion may mimic and impede ketamine
actions [87]. The application of AMPA receptor-blocking compounds may also inhibit ketamine’s
effects, thereby emphasizing the essentiality of these receptors as mediators of its antidepressant
action [68].
In order to exert its well-known rapid antidepressant effects, ketamine is compelled to activate
two transductional processes that have been regarded as fundamental: the GSK3 and the BDNF
pathways. GSK3 is a serine-threonine kinase, which has been crucially involved in depressive and
bipolar disorders [88,89], as seen in Figure 1. Using knock-in transgenic animals with serine-to-alanine
mutations to eliminate the inhibitory serines of GSK3, Beurel et al. demonstrated that when GSK3 cannot
be inhibited ketamine is not able to display the usual antidepressant effects in the learned helplessness
model of depression-like behavior [90]. Based on this study, other authors have reported that the add-on
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of lithium—a well-established GSK3 inhibitor—may potentiate the antidepressant effects of ketamine
and increase its anti-oxidative action in PFC of animal models of depressive behaviors [91,92].Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  8 of 22 
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in schizophreni 1; GSK3, glyc gen synthase kinase 3; GKAP, guanylate kinase associated protein;
H1a, Homer1a immediate-early inducible protein; PIP2, phosphatydilinositol bisphosph te; DAG,
diacylglycerol; IP3, inositol 1,4,5-trisphosphate; ER, end plasmic reticulum; PLC, phospholipase C; PKC,
protein kinase C; PP2A, protein phosphatase 2A; Akt1, RAC-α serine/thre nine-protein kinase; CAMK,
calcium-calmodulin regulated kinase; MAPKs, mitogen-activated r tein kinases; Erk, extracellular
ignal-regulated kinas ; MEK, MAPK/Erk kinase; Sh , Src homolog and collagen adaptor; Grb2, Growth
factor rece t r-bound protein 2; Gab1/2, Grb2-associated binder 1; PI3K, phosphoinositide 3 kinase;
mTOR, mammalian tar et of rapamycin; Raptor, Regulatory-associated protein of mTOR; mLST8,
mammalian lethal with SEC13 protein 8; p70S6K, ribosomal p70 S6 kinase; 4E-BP, 4E eukaryotic factor
binding protein; eIF-4B, eukaryotic initiation factor 4B; EF2K, Eukaryotic elongation factor 2 kinase.
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BDNF and mTOR pathways are tightly entangled and have been demonstrated to influence each
other with a complicated feedback mechanism, as seen in Figure 1. The activation of mTOR, induced
by the ketamine-mediated NMDA blockade, may de-suppress the protein translation machinery
controlled by eEF2 (see above), thus promoting hippocampal BDNF expression, which seems crucial
for ketamine’s antidepressant effects [82]. Indeed, in BDNF knock-out animals, ketamine is not able to
produce antidepressant effects, thus demonstrating the crucial role of BDNF in fast-acting responses
following ketamine administration [93]. Moreover, the release of BDNF from PFC neurons is essentially
mediated by post-synaptic AMPA receptor stimulation, which is concurrently activated by ketamine
NMDA blockade, and by the activation of L-type voltage-dependent calcium channels, which stimulate
the activity-dependent exocytosis of BDNF [94].
The release of BDNF promotes a lot of synaptic plasticity mechanisms and dendritic spine
modifications that have been proposed to underlie the long-term effects of ketamine administration [95],
as well as of other antidepressants [96]. Moreover, BDNF has been reported to start a feedback
re-stimulation of mTOR, through the activation of Tropomyosin receptor kinase B (TrkB) and its
downstream effectors ERK and Akt, which in turn activate mTOR, as well as through the increase
in synthesis and trafficking of AMPA receptors, thus increasing their signaling and AMPA-mediated
mTOR stimulation [97], as shown in Figure 1.
The role of BDNF in ketamine antidepressant action is confirmed by studies demonstrating
that ketamine efficacy is reduced in transgenic animals carrying the Val66Met BDNF mutation,
which impairs ketamine-mediated synaptogenesis by altering trafficking of BDNF to dendrites [98].
Considering that a quarter-to-a third of the population has been estimated to carry the Val66Met
BDNF mutation [99], this may account for the one third depressed patients who seem resistant to
ketamine’s effects.
3.3. Comparing Anti-Suicidal Treatment Neurobiology: Ketamine vs. Classical Antidepressants, Lithium
and Clozapine
Most of the data on the efficacy of classical treatments for suicidal behaviors rely on the efficacy of
these treatments on the pathologies they have been prescribed for. In fact, diverse controversies exist
on the efficacy of classical antidepressant treatments on both suicide ideation and attempts. Although
a lot of studies confirm that generally both tricyclic and selective serotonin reuptake inhibiting (SSRI)
antidepressants may lower the risk of suicide in treated patients [100–103], the FDA has given a warning
on the use of antidepressants based on the evidence that these drugs may increase suicidality in children
and adolescents [104]. These effects may depend upon the delayed action of antidepressant drugs,
as well as on the possible emergence during the treatment of agitation, insomnia, mixed symptoms,
and impulsivity, which are often perceived as unpleasant and may account for the increase in suicidal
impulses [105]. From a neurobiological point of view, the incomplete efficacy of classical antidepressant
treatment on suicidal behavior may be due to their selective modulation of serotonin neurotransmission,
which, as previously described, has been only partially implicated in the pathophysiology of suicide
processes. Indeed, although some polymorphisms in serotonergic neurotransmission-related genes
(i.e., tryptophan hydroxylase, serotonin transporter) have been associated with temperamental traits in
people prone to depression and suicide [106], no association has been found between polymorphisms
in serotonin receptors and suicidal behaviors [107]. A recent metanalysis found no correlation between
the 5-HTTLPR polymorphism and suicidal behavior, though a specific influence was found on the
increased risk of violent suicide [108]. These results contribute to defining serotonin signaling as a
part of the complex molecular machinery implicated in the pathophysiology of suicidal behaviors,
thereby relegating classical antidepressants to partial anti-suicidal treatments, often ineffective or
even counterproductive.
Differently from antidepressants, lithium treatment has been associated with a significant
reduction in suicide risk and suicide attempts in patients with bipolar disorder or major depressive
disorder, so much so that the American Psychiatric Association has put this statement in its Practice
Int. J. Mol. Sci. 2018, 19, 2888 10 of 22
Guidelines for the assessment of patients with suicidal behavior from 2003 [109]. These effects
have been confirmed in a recent metanalysis [110]. Interestingly, although for the most part of
anti-suicidal treatments achieve their objective by treating depressive correlates, lithium has been
described as reducing suicidal behaviors independently from mood improvement [111]. A large
body of evidence suggests that the anti-suicidal effects of lithium may rely on its action on multiple
levels of the suicidal process. Preclinical studies demonstrated that lithium may impact peculiar
endophenotypes associated with suicidal behaviors, such as impulsivity, an action that is not shared
with other mood stabilizers [112,113]. Differently from ketamine, whose effects may be measured in
terms of hours or days after administration, lithium efficacy on suicidal behaviors arises in long-term
treatment. However, a large amount of studies report that lithium anti-suicidal effects rely on
the modulation of neurobiological pathways which are also impacted substantially by ketamine.
Indeed, a crucial role in lithium transductional effects is exerted by GSK3 [114]. Through GSK3
activity regulation, lithium treatment may impact inflammatory cascades, which are mys-activated
by HPA axis dysregulation in mood disorders, and have been associated with suicide-related
impulsivity/aggression endophenotype [115]; moreover, as previously mentioned with regard to
ketamine, GSK3 modulation is essential for oxidative stress regulation as well as BDNF secretion,
both implicated in depressive disorders and suicidal behaviors [116]. GSK3 has been regarded also to
act as a molecular crossroad in serotonin transductional pathways, being dysregulated in behavioral
abnormalities induced in animal models of serotonin deficiency [117], thus representing a further
possible target of lithium action. Last, but not least, the modulation of GSK3 by lithium has been
regarded as a core target in the reinstatement of circadian rhythmicity disruption via the regulation
of CLOCK genes, whose dysfunction has been strongly implicated in suicidal behaviors in patients
suffering from major affective disorders [118].
Clozapine has been approved for the treatment of suicidal ideation in patients suffering from
schizophrenia. Although there is a large evidence of these effects, to date the mechanisms of
anti-suicidal properties of clozapine are still elusive. Some studies have suggested that clozapine
efficacy on suicidal behaviors in schizophrenia patients may parallel its efficacy on treatment-refractory
forms of the disorder, probably relying on the nonselective multireceptorial modulation exerted by this
drug [119]. In preclinical studies, clozapine, similarly to lithium, has been demonstrated to prevent
aggressive behaviors in animal models of depressive states, which represent an endophenotype of
suicidal behavior in humans [120]. Clozapine appears efficacious also in controlling pro-suicidal traits
in two-hit animal models of schizophrenia showing aggressiveness, impulsivity, hopelessness, and
anxiety [121]. Moreover, the well-known modulation by clozapine of 5HT1a receptors, which leads
to an increase in PFC dopamine release, has been involved in the clinical efficacy of this drug on
both negative and cognitive symptoms of schizophrenia, whose treatment-refractoriness has been
associated in turn to the propension to suicidal ideation in patients [122]. As in the case of ketamine
and lithium, clozapine’s anti-suicidal effects seem to depend upon the modulation of multiple, and
in large part unknown, transduction pathways. In order to confirm these theories, a recent study
demonstrated that the beneficial effects of clozapine in reverting pro-suicidal like endophenotypes in
two-hit animal models of schizophrenia may be impaired by the administration of the antiandrogen
finasteride, thus suggesting a complex interaction between clozapine and neurosteroid signaling in the
regulation of suicidal behavior [123].
4. Eradicating the Roots of Suicide: Clinical Randomized Studies of Anti-Suicidal Effects
of Ketamine
For the purpose of this review only randomized clinical trials (RCT) were evaluated to investigate
the efficacy of i.v. ketamine or intranasal esketamine on suicidal ideation. The efficacy of ketamine and
esketamine has been evaluated in several randomized trials (see Table 1).
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Table 1. Randomized clinical trial of ketamine and esketamine on suicide ideation and risk.
Authors Year Study Sample Study Design Comparator Number ofSubject Study Aims Ketamine Dose Main Findings
Canuso et al. 2018 Subjects with MDD andsuicidal ideation
Randomized,
placebo-controlled
trial
Intranasal
Placebo 68
To compared the efficacy of
standard-of-care treatment plus
intranasal esketamine or placebo
for rapid reduction of symptoms
of MDD, including suicidality
Intranasal
esketamine (84 mg)
twice weekly for 4
weeks
Intranasal esketamine compared with
placebo, given in addition to
comprehensive standard-of-care
treatment, may result in significantly
rapid improvement in depressive
symptoms, including suicidal ideation
Grunebaum
et al. 2018
Tested the acute effect of
adjunctive subanesthetic
intravenous ketamine on
clinically significant
suicidal ideation in
patients with MDD
Randomized,
controlled trial Midazolam 80
To test the acute effect of
adjunctive subanesthetic
intravenous ketamine on clinically
significant suicidal ideation in
MDD
0.5 mg/kg infused
over 40 min
Adjunctive ketamine demonstrated a
greater reduction in clinically
significant suicidal ideation in
depressed patients within 24 h
compared with midazolam, partially
independently of antidepressant effect
Grunebaum
et al. 2017
Subjects with bipolar
depression and suicidal
ideation
Pilot, randomized,
controlled trial Midazolam 16
To evaluate feasibility and effects
of a sub-anesthetic infusion dose of
ketamine versus midazolam on
suicidal ideation in bipolar
depression
0.5 mg/kg infused
over 40 min
Suicidal thoughts were lower after
ketamine than after midazolam at a
trend level of significance
Fan et al. 2017 Cancer patients withsuicidal ideation
Randomized,
controlled trial Midazolam 37
To evaluate the rapid
antidepressant effects of single
dose ketamine on suicidal ideation
and overall depression level in
patients with newly-diagnosed
cancer
0.5 mg/kg infused
over 40 min
Antidepressant and anti-suicidal
effects of ketamine were significantly
seen as soon as 1 day following
administration and typically lasted for
at least 3 days
Burger et al. 2016
Individuals presenting
with suicidal thinking in
a military setting
Randomized,
placebo-controlled
trial
Normal saline
(placebo) 10
To evaluate the potential benefits
of ketamine vs. placebo
administered to individuals
presenting with suicidal thinking
in a military setting
0.5 mg/kg infused
over 40 min
Two of three who received ketamine
experienced dramatic decreases in
suicidality and hopelessness within 40
min
Hu et al. 2016 Thirty outpatients withsevere MDD
Randomized,
placebo-controlled
4-week study
combined with
escitalopram 10 mg
Normal saline
(placebo) 30
To evaluate the antidepressant and
anti-suicidal effects of single i.v.
ketamine combined with
escitalopram initiation in MDD
0.5 mg/kg infused
over 40 min
Single-dose i.v. ketamine showed an
attenuation of the antidepressant
effects by the end of week 1. Suicidal
ideation improved significantly, which
was sustained for up to 10 days
Murrough et
al. 2016
Subjects with mood and
anxiety disorders
spectrum
Randomized,
controlled trial Midazolam 24
To evaluate acute effect of i.v.
ketamine on clinically significant
suicidal ideation in patients with
mood and anxiety disorders
spectrum
0.5 mg/kg infused
over 40 min
A single adjunctive ketamine infusion
was associated with a clinically
significant reduction in suicidal
ideation at 48 h that was greater than
with the midazolam control infusion
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Table 1. Cont.
Authors Year Study Sample Study Design Comparator Number ofSubject Study Aims Ketamine Dose Main Findings
Price et al. 2014
Symptomatic patients
with treatment-resistant
MDD
Randomized,
controlled trial Midazolam 57
To evaluate acute effect of i.v.
ketamine vs midazolam on explicit
and implicit suicidal cognition
0.5 mg/kg infused
over 40 min
i.v. ketamine showed rapid reductions
in suicidal cognition over and above
midazolam
Zarate et al. 2012
Subjects with DSM-IV
bipolar I or II depression
maintained on
therapeutic levels of
lithium or valproate
Double-blind,
randomized,
crossover,
placebo-controlled
study
Normal saline
(placebo) 15
To evaluate acute effect of i.v.
ketamine on clinically significant
suicidal ideation in patients with
bipolar depression
0.5 mg/kg infused
over 40 min
Within 40 min, depressive symptoms,
as well as suicidal ideation,
significantly improved in subjects
receiving ketamine compared with
placebo and this improvement
remained significant through day 3
Kudoh et al. 2002
Depressed patients who
had undergone
orthopedic surgery
Randomized study.
Patients in Group A
were induced with
propofol, fentanyl,
and ketamine and
patients in Group B
were induced with
propofol and
fentanyl
Propofol,
fentanyl 95
To evaluate acute effect of i.v.
ketamine on clinically significant
suicidal ideation in depressed
patients who had undergone
orthopedic surgery
0.5 mg/kg
combined with
propofol and
fentanyl
Depressed mood, suicidal tendencies,
somatic anxiety, and hypochondriasis
significantly decreased in Group A as
compared with Group B
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Since early studies, ketamine infusion (0.5 mg/kg) mixed with other anesthetic drugs (propofol,
fentanyl) used to induce anesthesia in depressed patients undergoing orthopedic surgery was
demonstrated to improve both depression and postoperative pain already one day after surgery [124].
The incredible speed of antidepressant action by ketamine has been repeatedly reported in successive
RCTs, starting from Zarate et al. [125], who demonstrated that the first effects on depressive symptoms
and suicidal thoughts may be seen only 40 min after ketamine injection (0.5 mg/kg 40 min i.v. infusion)
in bipolar patients, and persist stably for three days, then gradually decreasing in the next two weeks,
with only few patients maintaining results at this time point. Dissociative symptoms have been seen in
the most part of patients, though not reaching impairing severity.
Similar results have been replicated in several RCTs, as shown in Table 1, demonstrating
that ketamine infusion has rapid antidepressant and anti-suicidal effects starting soon after the
administration, and lasting for a few (3–14) days with scarce side effects. This formidable action
may be observed in all major affective disorders, and it seems independent from the concomitant
medications administered (especially antidepressants or mood stabilizers).
Given the controversial literature reports on the major antidepressant effects of the administration
of single isomers of ketamine rather than the racemic mixture [126], recent studies have focused on
the possible administration of S-ketamine (esketamine, which is considered the most active and less
damaging isomer) by intranasal administration. The administration of intranasal esketamine (84 mg)
has been demonstrated to induce soon antidepressant effects (within 4 h), rapidly diminishing (up to a
week) with scarce side effects (mostly dissociation, dizziness, and headache), and a peculiar action on
suicidal thoughts, which rapidly decrease within 4 h from administration. However, these effects do
not persist significantly after 24 h [127].
Overall, all reviewed trials demonstrated an efficacy of ketamine [125,128–135] and
esketamine [127] in reducing suicidal ideation in patients with MDD, bipolar depression, cancer
or other conditions. These results were also confirmed by a meta-analysis (based on 10 earlier open
and randomized trials) that found that a single ketamine infusion rapidly reduced the severity of
suicidal thinking, within 24 h in more than half the patients, and with benefits observed for up to
1 week. However, our review, even if not systematic, but narrative, included most recent trials and
corroborated this observation.
The most common adverse effects (AEs) of ketamine were nausea, transient elevations in blood
pressure (with intranasal formulation), drowsiness, dizziness, poor coordination, blurred vision,
and feelings of strangeness or unreality, but these were not considered to be problematic for the
subjects [125,127–135]. However, dissociative and psychotomimetic AEs occurred more commonly
with ketamine, but were short-lasting and clinically not significant [127–129].
However, despite the potential benefits of ketamine as a “crisis” treatment for subjects with high
suicide risk [136,137], there are still several concerns on its use as pointed out by Nemeroff [138] in a
recent Editorial published on the American Journal of Psychiatry.
Obviously, the major concern is that ketamine is a substantial drug of abuse worldwide. This may
be somewhat problematic, even if the employed dosages in randomized trials were very low, as it may
promote abuse in predisposed subjects as reported after the conclusion of one trial [128] and other
observations [138,139]. Furthermore, Nemeroff [138] underlines that many ketamine clinics that are
operating in the USA do not follow the minimal recommendations of a recent American Psychiatric
Association consensus report [140] and may result in the off-label prescribing of ketamine for patients
with psychiatric disorders without a strong recommendation for its use [141].
Moreover, though there is robust evidence that ketamine may offer significant short-term benefits
to many individuals suffering from possibly fatal mood disorders due to high suicide risk, this
treatment has not yet undergone the test of multiple large-scale trials to determine the durability and
safety of long-term treatment. Only Grunebaum et al. [128] found that a significant anti-suicidal effect
was maintained for up to 6 weeks when combined with optimized pharmacotherapy, but there is a
lack of studies that evaluated the ketamine effect on suicidal ideation after 6 weeks.
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5. Eradicating the Roots of Suicide with Ketamine Treatment: Conclusions
Overall, the mechanism of action of ketamine in the treatment of suicidal patients involves several
pathways but, first of all, the glutamatergic system seems to play a pivotal role [142]. In fact, it has been
suggested that a glutamate neurotransmission dysregulation may be the basis of suicidal cognitive
biases, explaining the benefits of ketamine treatment [53,143]. Ketamine is a non-selective NMDA
receptor antagonist acting at opened channels, but several studies have identified multiple receptor
interactions of ketamine, such as with opioid sigma and mu receptors, serotonin 5HT3 receptors,
muscarinic receptors, α7 nicotinic acetylcholine receptors, and cathecolamines transporters, localizing
the principal sites of action of this compound in PFC and hippocampal brain areas [144]. Therefore
all these ketamine actions on neurotransmitters and selected brain areas may further contribute to its
antidepressant and anti-suicidal properties [145].
Moreover, to explain its well-known rapid antidepressant and anti-suicidal effects, ketamine is
compelled to activate two transductional processes that have been regarded as fundamental: the GSK3
and the BDNF pathways [146,147]. Also, ketamine action on mTOR-dependent pathways may further
contribute to its rapid effects [148,149].
Concerning clinical trials, the results of this narrative review demonstrated a remarkable and fast
efficacy of ketamine and esketamine (within 24 h in more than half of the patients, and with benefits
observed for up to 1 week) in reducing suicidal ideation in patients with MDD, bipolar depression,
cancer or other conditions. The most common adverse effects (AEs) of ketamine weren’t considered to
be problematic in clinical randomized trials even if dissociative and psychotomimetic AEs occurred
more commonly with ketamine than comparators (midazolam or placebo).
However, despite the potential benefits of ketamine as a “crisis” treatment of a subjects with high
suicide risk, there are still several concerns on its use and the main may be the potential abuse of
this compound and the lacking of multiple large-scale trials to determine the durability and safety of
long-term ketamine treatment [136,141].
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